Mangrove Partners’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

Mangrove Partners’s Portfolio DMAQR Stock Details DMAQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,485,437	Closed	-$238K	–	206
2023 Q2	$238K	Sell	1,485,437 -14,563	-1%	-$2.38K	0.02%	179
2023 Q1	$218K	Hold	1,500,000	–	–	0.01%	213
2022 Q4	$90K	Hold	1,500,000	–	–	0.01%	339
2022 Q3	$59K	Hold	1,500,000	–	–	﹤0.01%	366
2022 Q2	$165K	Hold	1,500,000	–	–	0.01%	476
2022 Q1	$270K	Hold	1,500,000	–	–	0.01%	410
2021 Q4	$480K	Buy	+1,500,000	New	+$474K	0.03%	465

Other funds holding DMAQR

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Mangrove Partners's DMAQR Position: Q3 2023 in Review

Mangrove Partners sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q3 2023, closing a stake of 1,485,437 shares — an estimated $238K sold.

Mangrove Partners first reported a position in DMAQR in Q4 2021 and held it in 7 quarters. The position peaked at $480K in Q4 2021. 26 funds tracked by Wall St. Rank hold DMAQR as of Q3 2023.

Mangrove Partners reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q3 2023 after selling out during the quarter.
Mangrove Partners sold 1,485,437 Deep Medicine Acquisition Corp. Rights shares in Q3 2023, an estimated $238K.
Mangrove Partners first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 7 quarters.
Mangrove Partners's Deep Medicine Acquisition Corp. Rights position peaked at $480K in Q4 2021.
26 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q3 2023.

Based on Mangrove Partners's 13F filing for Q3 2023, filed 14 Nov 2023.